E Portola Pharmaceuticals Inc. Is A Stock To Watch With Caution Ahead Of PDUFA

Almost certainly, it would be enough to reverse the year to date losses, with expectations of a 30-50% upside on current price not unreasonable.

Of course, there's the risk that the FDA will turn the drug down. Given current sentiment (weak) and the condition of its other lead candidate (unconvincing) this would severely hit Portola's market capitalization. An FDA decline outright, or a CRL, will likely catalyze a similar decline to that we saw in March, and potentially even more severe depending on the response.

One to watch, with caution. PDUFA is August 17, 2016. 

1 2 3
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.